Kindred Biosciences, a biotech developing pet therapeutics for pain and severe itching, raised $53 million by offering 7.5 million shares (up from 5.8 million) at $7, the midpoint of the range of $6 to $8. Kindred Biosciences plans to list on the NASDAQ under the symbol KIN. Kindred Biosciences initially filed confidentially on 10/2/2013. BMO Capital Markets and Guggenheim Securities acted as joint bookrunners on the deal.
